corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) + human Chorion Gonadotropin (hCG) + hCG Bolus injection
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovulation Induction
Conditions
Ovulation Induction
Trial Timeline
May 15, 2007 → May 15, 2008
NCT ID
NCT00697255About corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) + human Chorion Gonadotropin (hCG) + hCG Bolus injection
corifollitropin alfa + recombinant Follicle Stimulating Hormone (recFSH) + human Chorion Gonadotropin (hCG) + hCG Bolus injection is a phase 2 stage product being developed by Organon for Ovulation Induction. The current trial status is terminated. This product is registered under clinical trial identifier NCT00697255. Target conditions include Ovulation Induction.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00702338 | Pre-clinical | Completed |
| NCT00697255 | Phase 2 | Terminated |
Competing Products
13 competing products in Ovulation Induction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR7280 tablets | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Follitropin alpha (r-FSH) | Merck | Pre-clinical | 23 |
| Recombinant FSH (follitropin alpha) | Merck | Approved | 85 |
| MSJ-0011 + urinary hCG (u-hCG) + Follitropin alpha | Merck | Phase 3 | 77 |
| Lutropin alfa + Follitropin alfa | Merck | Approved | 85 |
| AS900672-Enriched 10 microgram (mcg) + AS900672-Enriched 20 mcg + AS900672-Enriched 30 mcg + AS900672-Enriched 40 mcg + Follitropin alfa 75 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG) | Merck | Phase 2 | 52 |
| Orlistat Vs Metformin | Roche | Pre-clinical | 23 |
| Levonorgestrel + Ethinyl Estradiol | Pfizer | Phase 2 | 51 |
| EV/DNG (Qlaira, BAY86-5027, SH T00658K) + EV/DNG (SH T00658L) | Bayer | Phase 2 | 49 |
| Myo-inositol + Clomiphene Citrate | Richter Gedeon | Approved | 82 |
| usual administration of exogenous recombinant FSH | Organon | Pre-clinical | 18 |
| Follitropin beta | Organon | Pre-clinical | 18 |